Completed PHASE2 INTERVENTIONAL 2-arm NCT00425334

Safety Study of Hemospan® in Prostatectomy Patients

A Clinical Safety (Phase II) Increasing Dose Study of MP4 (Hemospan®) in Total Prostatectomy Surgical Patients

Sponsor: Sangart

Conditions Blood Loss, Surgical Prostate Cancer Surgery

Interventions Hemospan (MP4OX) Ringer's lactate

Updated 6 times since 2017 Last updated: Aug 15, 2013 Started: Jul 31, 2005 Primary completion: Oct 31, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Blood Loss, Surgical and Prostate Cancer and is currently completed. Sangart leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sangart

Data source: Sangart

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States